Imperagen, a Manchester-based biotech firm, has secured €5.8 million in seed funding to enhance its innovative enzyme engineering platform, which utilizes AI and quantum simulation technologies.
Recently, Imperagen announced the closing of a £5 million (~€5.8 million) seed funding round led by PXN Ventures, with participation from existing investors IQ Capital and Northern Gritstone. This funding brings the company's total investment to £8.5 million since its inception in 2021. The new capital will be used to expand its AI team, develop wet lab facilities, and drive market entry across various sectors, including pharmaceuticals and industrial biotech.
Imperagen's platform, known as Digital Enzyme Evolution, integrates quantum physics-based simulations, custom AI models, and robotic automation to significantly enhance enzyme performance. The system has demonstrated remarkable efficiency, achieving a 677-fold increase in enzyme productivity within just five iterations. This approach addresses the limitations of traditional trial-and-error methods in enzyme development, positioning Imperagen as a leader in the rapidly growing enzyme engineering market, expected to reach $4.94 billion by 2032.
The timing of this funding round aligns well with increasing global demand for enzyme engineering services and regulatory support for sustainable manufacturing practices. As the market for AI-generated enzymes expands, Imperagen's innovative methodology and the recent appointment of CEO Guy Levy-Yurista signal a strategic shift towards commercial viability. This development presents a promising opportunity for the UK biotech sector, particularly in the intersection of quantum technology and industrial applications.